RapidPlan lung SBRT model used gEUD objectives for reproducible planning
A RapidPlan lung SBRT model generated clinically acceptable plans in 52% of validation cases on first optimization.
A RapidPlan lung SBRT model generated clinically acceptable plans in 52% of validation cases on first optimization.
Single-field optimization improved proton LATTICE motion robustness
BED >37.5 Gy improved symptomatic control, while 6-month local control remained 46% in frail, elderly, or metastatic rectal cancer.
High-dose carbon ion re-irradiation achieved 83.1% 3-year survival with no grade 4 toxicity in recurrent pelvic sarcoma.
CT-guided online adaptive prostate SBRT was feasible, with adapted plans selected in 95% of fractions and dosimetric improvements in 85%.
Concurrent polatuzumab vedotin and radiotherapy was feasible in heavily pretreated aggressive B-cell lymphoma without unexpected acute or subacute toxicity.
Twice-weekly 28 Gy in 5 fractions produced no grade 3 or higher toxicity and 98.8% excellent-to-good cosmesis at 1 year.
Concurrent neoadjuvant radiotherapy shortened treatment duration but did not improve pathological complete response or survival.
This systematic review found that optimal radiotherapy-immunotherapy sequencing depends on the immune mechanism being targeted.
VMAT-based lattice SFRT achieved cross-platform deliverability with gamma pass rates above 90% and preserved peak-to-valley dose ratios.
MIM-based skeletal muscle index measurement matched ImageJ while reducing processing time from 10 to 3.5 minutes.
A center-specific federated learning model predicted grade 2 or higher radiation pneumonitis with stable cross-dataset performance.
Single-fraction GammaPod partial breast irradiation produced 12.1% fat necrosis and 4.1% symptomatic fat necrosis in a phase 2 trial.
RapidPlan reduced several organ-at-risk dose metrics while maintaining comparable target coverage in head and neck and brain radiotherapy planning.
TREASURE found no survival benefit and higher serious toxicity with thoracic radiotherapy added to atezolizumab maintenance.